Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.55 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.55 |
| ▸ | DUT | P33316 | 3/20 | 0.51 |
| ▸ | TK1 | P04183 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TK2 | O00142 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25718129 | 1.00 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL22916864 | 1.00 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL13790692 | 1.00 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL26189587 | 1.00 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL26267937 | 0.88 | DUT (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL26233420 | 0.88 | DUT (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL26268732 | 0.88 | DUT (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| Deoxyuridine SCHEMBL24512520 | 0.85 | DUT (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL8182746 | 0.85 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| Deoxyuridine SCHEMBL114598 | 0.85 | DUT (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093737-A1 | Nucleoside and Nucleotide Analogues with Quaternary Carbon Centers and Methods of Use | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093737-A1 | Nucleoside and Nucleotide Analogues with Quaternary Carbon Centers and Methods of Use | NUDT1, NT5C3B, NTPCR | SLC28A1 38/4885SLC28A2 53/4885SLC29A1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.